Literature DB >> 22246586

Natural history of human aberrant crypt foci and correlation with risk factors for colorectal cancer.

Hidenori Ohkubo1, Hirokazu Takahashi, Eiji Yamada, Eiji Sakai, Takuma Higurashi, Takashi Uchiyama, Kunihiro Hosono, Hiroki Endo, Masataka Taguri, Atsushi Nakajima.   

Abstract

Although aberrant crypt foci (ACF) are estimated to have potential usefulness as a biomarker for colorectal carcinoma (CRC), this remains uncertain because the natural history of ACF has not been well-clarified. To determine the usefulness of ACF as a surrogate marker for CRC, it is necessary to understand the natural history of ACF. A total of 82 subjects who underwent total colonoscopy and whose ACF number was examined at least 2 times at Yokohama City University Hospital were enrolled. We retrospectively evaluated the changes in the ACF number at four different surveillance periods (6 months, 1 year, 2 years, 3 years) and in groups with and without colorectal neoplasms. Furthermore, we classified the subjects into an increased ACF group and a no change/decreased ACF group, and investigated the relationship between the changes in the ACF number and known risk factors for CRC. No significant differences were observed in the ACF number between the first and second observations in any surveillance period groups, and in the groups classified according to the presence or absence of colorectal neoplasms. There were no significant differences between the increased and no change/decreased ACF group in terms of gender, smoking habit, current alcohol consumption, age, BMI, HbA1c or serum triglyceride level (TG), whereas a significant difference between the groups was observed in the serum total cholesterol level (TC) (p=0.012). ACF are a reliable surrogate marker that are not affected by any risk factors for adenomas or CRC, except TC, and may therefore be considered as a useful marker in chemopreventive trials.

Entities:  

Mesh:

Year:  2012        PMID: 22246586     DOI: 10.3892/or.2012.1631

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Relationship of human rectal aberrant crypt foci and formation of colorectal polyp: One-year following up after polypectomy.

Authors:  Hirokazu Takahashi; Eiji Yamada; Hidenori Ohkubo; Eiji Sakai; Takuma Higurashi; Takashi Uchiyama; Kunihiro Hosono; Hiroki Endo; Atsushi Nakajima
Journal:  World J Gastrointest Endosc       Date:  2012-12-16

2.  Association between factors associated with colorectal cancer and rectal aberrant crypt foci in humans.

Authors:  Akiko Ezuka; Eiji Sakai; Kenichi Kawana; Hajime Nagase; Yukio Kakuta; Shiori Uchiyama; Hidenori Ohkubo; Takuma Higurashi; Takashi Nonaka; Hiroki Endo; Hirokazu Takahashi; Atsushi Nakajima
Journal:  Oncol Lett       Date:  2015-09-29       Impact factor: 2.967

3.  The distribution of human rectal aberrant crypt foci and criteria for defining the counting area.

Authors:  Tetsuro Fujii; Eiji Sakai; Hirokazu Takahashi; Eiji Yamada; Hidenori Ohkubo; Takuma Higurashi; Atsushi Nakajima
Journal:  Oncol Lett       Date:  2017-04-07       Impact factor: 2.967

4.  Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial.

Authors:  Takuma Higurashi; Kunihiro Hosono; Hiroki Endo; Hirokazu Takahashi; Hiroshi Iida; Takashi Uchiyama; Akiko Ezuka; Shiori Uchiyama; Eiji Yamada; Hidenori Ohkubo; Eiji Sakai; Shin Maeda; Satoshi Morita; Yutaka Natsumeda; Hajime Nagase; Atsushi Nakajima
Journal:  BMC Cancer       Date:  2012-09-19       Impact factor: 4.430

5.  The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial.

Authors:  Takuma Higurashi; Jun Arimoto; Keiichi Ashikari; Tomohiro Takatsu; Noboru Misawa; Tsutomu Yoshihara; Tetsuya Matsuura; Akiko Fuyuki; Hidenori Ohkubo; Atsushi Nakajima
Journal:  BMC Cancer       Date:  2020-08-17       Impact factor: 4.430

6.  The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial.

Authors:  Takuma Higurashi; Jun Arimoto; Keiichi Ashikari; Tomohiro Takatsu; Noboru Misawa; Tsutomu Yoshihara; Tetsuya Matsuura; Akiko Fuyuki; Hidenori Ohkubo; Atsushi Nakajima
Journal:  BMC Cancer       Date:  2020-10-29       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.